Key Takeaways
- Moderna shares climbed more than 16% following the publication of Phase 3 data for its mRNA flu vaccine (mRNA-1010) in the New England Journal of Medicine, demonstrating superior efficacy compared to a standard-dose influenza vaccine in individuals aged 50 and above.
- Following Moderna’s Q1 2026 earnings report, three Wall Street analysts increased their price targets: Evercore ISI to $50, Goldman Sachs to $49, while Piper Sandler launched coverage with a Buy recommendation.
- A hantavirus outbreak on a South Atlantic cruise briefly drew market attention to Moderna’s experimental hantavirus program, though experts emphasize the commercial opportunity remains negligible.
- The FDA has designated August 5 as the PDUFA target date for mRNA-1010, while regulatory submissions are also pending in Europe, Canada, and Australia.
- Pfizer and BioNTech discontinued recruitment for a major U.S. COVID vaccine study targeting the 50–64 age group due to insufficient enrollment.
Moderna shares were hovering near $56 on Thursday, reflecting a gain exceeding 16%, propelled by robust clinical trial outcomes, multiple analyst endorsements, and peripheral attention from hantavirus-related news.
The primary catalyst was clear-cut: Phase 3 clinical trial outcomes for Moderna’s investigational mRNA influenza vaccine, mRNA-1010, appeared in the New England Journal of Medicine. The published results demonstrated that the vaccine achieved its predefined superiority endpoint when compared to an approved standard-dose seasonal influenza vaccine in adults 50 years and older.
This represents a significant regulatory milestone. Demonstrating superiority over an existing licensed vaccine in a prestigious peer-reviewed publication strengthens Moderna’s submission as it approaches a critical FDA decision point.
The FDA has established August 5 as the PDUFA target date for mRNA-1010. Additionally, regulatory authorities in Europe, Canada, and Australia are reviewing submissions, positioning this as a potentially global product launch pending approvals.
Analyst endorsements amplified the rally. Evercore ISI boosted its price target from $35 to $50. Goldman Sachs increased its target from $43 to $49. Piper Sandler launched coverage with a Buy recommendation. These three moves followed Moderna’s Q1 2026 earnings release.
Hantavirus Outbreak Created Short-Lived Buzz
A hantavirus cluster involving travelers on a cruise ship sailing from Argentina to Cabo Verde temporarily elevated Moderna shares during early trading hours. Eight individuals contracted the virus, with three fatalities reported, and five cases identified as the Andes virus strain — the sole hantavirus variant capable of limited person-to-person transmission.
The World Health Organization assessed the public health threat as minimal. Dr. Maria Van Kerkhove emphasized at Thursday’s press briefing: “This is not the start of a COVID pandemic.”
Evercore ISI highlighted a Moderna partnership with Korea University on hantavirus research initiated in 2023, but tempered expectations significantly. The firm stated it identifies “no meaningful revenue opportunity” arising from the outbreak headlines and emphasized that Moderna’s hantavirus candidate “remains very early stage.” The stock, analysts noted, “tends to trade on outbreak headlines well beyond the underlying commercial implications.”
Bottom line: while the hantavirus news captured headlines, the influenza vaccine publication and analyst upgrades were the genuine market movers.
Cruise Industry Stocks Declined on Health Concerns
Cruise operator stocks experienced declines following the hantavirus reports. Royal Caribbean dropped approximately 2% during the session, while Carnival posted similar losses. Norwegian Cruise Line Holdings fell nearly 3%. Viking Holdings and Lindblad Expeditions each declined roughly 2.5%.
On the competitive landscape, Pfizer and BioNTech terminated enrollment for an extensive U.S. COVID vaccine clinical trial focused on adults between 50 and 64, attributing the decision to inadequate participation rates. This development could potentially strengthen Moderna’s competitive standing in the next-generation vaccine market.
Broader equity markets provided a favorable backdrop, with the S&P 500 advancing 0.71%, the Dow Jones gaining 0.21%, and the Nasdaq climbing 1.16%.
Moderna’s stock finished the previous trading session at $48.79. The August 5 FDA decision deadline for mRNA-1010 represents the next significant catalyst for the company.
